Skin Cancer
ECOG-ACRIN EA6141
Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma
Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together.
Status:
Recruiting